Strive Pharmacy

• Pharmacy Profile Name: Strive Pharmacy (strivepharmacy.com)
• HQ: Gilbert, AZ
• Pharmacy Type: 503A compounding pharmacy
• Accreditations: NABP + PCAB + LegitScript (triple-accredited)
• GLP-1 Products: Semaglutide, Tirzepatide (injectable; 90-day BUD; glycine + B12)
• Licensed: All 50 states
• Founded: 2018
• Telehealth Partners: Lavender Sky Health, Mochi Health; formerly Hims & Hers

About the Pharmacy

Strive was founded in 2018 from a conviction that healthcare should be accessible, adaptable, and formulated around patients’ unique needs, with a focus on bringing personalization, precision, and compassion back to medicine.

In October 2024, Strive announced the acquisition of a nearly 50,000 square-foot facility in St. Louis, Missouri, intended to house pharmaceutical compounding, warehouse operations, and custom fulfillment services in a vertically integrated model designed to serve telehealth companies at scale. With nine locations across the country and all 50 state licenses, Strive is among the most geographically expansive 503A compounding operations in the GLP-1 space.

GLP-1 Compounding

Strive Compounding Pharmacy compounds semaglutide and tirzepatide, as well as Amlexanox and other weight management medications. Standard injectable formulations combine the GLP-1 active ingredient with glycine and B12. The pharmacy maintains 90-day beyond-use dates on its GLP-1 products, with ingredients sourced exclusively from FDA-registered, GLP-1 “Green List” facilities per the pharmacy’s published quality standards.

Strive sources GLP-1 ingredients exclusively from FDA official “GLP-1 Green List” facilities, with each ingredient shipment arriving with a Certificate of Analysis verifying authenticity and purity.

Type of Pharmacy

Strive is a 503A compounding pharmacy — the largest and most nationally distributed 503A operation in this review series. Its accreditation stack is notably strong:

Strive is voluntarily accredited by the National Association of Boards of Pharmacy (NABP), the Pharmacy Compounding Accreditation Board (PCAB), and LegitScript, and is licensed in all 50 states.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

Regulatory History — significant:

February 2024 — Arizona Board of Pharmacy consent agreement: In a February 2024 consent agreement, the Arizona Board of Pharmacy stated that Strive began compounding injectable semaglutide in August 2021 — approximately seven months before semaglutide was added to the FDA’s drug shortage list. Strive agreed to pay a $1,000 fine.

February 2025 — Hims & Hers oral semaglutide controversy: Strive manufactured the oral compounded semaglutide pill that Hims & Hers launched on February 5, 2025, using what Strive described as “liposomal technology.” Hims pulled the product two days after launch after coming under federal scrutiny. Questions also arose about whether the product would work without Novo Nordisk’s patented coating, and Hims and Strive’s claimed liposomal technology has not been proven in clinical trials to be effective in humans. Novo Nordisk subsequently sued Hims for patent infringement. Strive has since removed related website pages and social media posts, stating the language was “being misunderstood.”

April 1, 2025 — Eli Lilly lawsuit: Eli Lilly sued Strive in Delaware and New Jersey, alleging the company was falsely marketing its tirzepatide products as personalized and clinically tested when Lilly argues Strive was mass-producing standardized versions of tirzepatide to skirt the FDA’s ban on compounding after the shortage ended. Lilly’s complaint alleged Strive sells tirzepatide combined with glycine and vitamin B12, claiming it is a custom-made “personalized” product, but that Strive does not sell personalized tirzepatide at all — instead mass-producing a single standardized tirzepatide combination drug under the false premise that it is tailor-made for each patient.

September 4, 2025 — Arizona BOP inspection: A September 2025 inspection of Strive’s Gilbert, Arizona facility by the Arizona Board of Pharmacy found that Strive continued to compound and dispense single-ingredient versions of semaglutide and tirzepatide after the federal shortage exemption period ended. An inspector wrote that Strive produced “large amounts of odd strengths/doses in anticipation of prescriptions,” and that different providers whose prescriptions were fulfilled by Strive used identical language to justify compounding what regulators described as “essential copies” of commercially available FDA-approved GLP-1 drugs. The Arizona BOP is also taking up additional complaints alleging misuse of ketamine at Strive’s facilities and providing prescription drugs to a clinic that was selling them over the counter.

January 2025 — Strive counter-lawsuit: Strive filed its own lawsuit against Eli Lilly and Novo Nordisk, alleging the drug manufacturers used exclusive telehealth deals and other anticompetitive tactics to squeeze compounding pharmacies out of the GLP-1 market.

No FDA Warning Letter specifically targeting Strive Pharmacy’s manufacturing operations was found in FDA public records as of March 2026.

States Licensed In

Strive is licensed in all 50 states.

Telehealth Providers They Work With

Strive supplies compounded tirzepatide and semaglutide to telehealth platforms, including Lavender Sky Health and Mochi Health. Its former relationship with Hims & Hers ended in February 2025 following the oral semaglutide controversy. Strive’s nine locations and St. Louis fulfillment hub are positioned explicitly to serve telehealth companies at scale, and the pharmacy actively recruits provider and telehealth partners through its website.

Pricing from Reviews

Strive does not publish consumer-facing GLP-1 pricing; rates flow through the prescribing telehealth platform or clinic. The pharmacy’s positioning as a premium, triple-accredited national operation, described by some patients as a “luxury pharmacy,” suggests pricing at the higher end relative to bare-bones compounders, though exact figures depend on the platform partner.

Overall Reviews

Strive holds over 1,500 reviews on Birdeye with generally positive patient and provider feedback, with reviewers citing high product quality, professional onboarding for clinic partners, and FedEx overnight shipping. Patient community sentiment on TikTok describes Strive as one of the higher-quality options among compounding pharmacies. First-order turnaround is occasionally noted as slower than subsequent refills.

The regulatory picture, however, is complicated. Strive’s triple accreditation and published quality standards coexist with a meaningful accumulation of compliance concerns: the 2024 Arizona consent agreement for pre-shortage compounding, the 2025 Hims oral semaglutide controversy involving unproven technology, the Eli Lilly lawsuit alleging mass production under a “personalized” cover, and the September 2025 Arizona BOP inspection findings about post-shortage compounding and identical provider justification language. Strive disputes many of these characterizations and has actively litigated to defend its compounding practices.